



## AlzeCure initiates clinical Phase I trial with ACD855 - first dose in humans

**AlzeCure Pharma AB (publ) (FN STO: ALZCUR) today announced it has started dosing of the first subjects in a clinical Phase I trial with its leading compound ACD855 within the platform NeuroRestore.**

This follows the recently obtained approval of the study by the Swedish Medical Product Agency and the responsible ethics committee to commence clinical Phase I trials for the drug candidate ACD855 from the NeuroRestore platform. AlzeCure has today initiated treatment of the first patients in this study which is a double-blind, placebo-controlled, randomized first-in-human study to evaluate safety, tolerability, pharmacokinetics and CNS pharmacodynamics for ACD855. The start of the clinical study is according to plan and this leading drug candidate aims to treat patients suffering from cognitive disorders, such as Alzheimer's disease. The results of the study are expected to be completed by mid-2020.

"Commencing the treatment of patients in the phase I trial is an important milestone for the company. ACD855 has the potential to improve cognition in a variety of disorders, including Alzheimer's and might thus become a very important treatment to improve the quality of life for patients. The fact that ACD855 is administered orally will also be a great advantage for the patients," says AlzeCure's CEO Johan Sandin.

*The information was submitted for publication, through the agency of the contact person set out below, at 10.45 CET on December 12, 2018.*

### **For more information, please contact**

Johan Sandin, CEO  
Tel: +46 703 738 824  
johan.sandin@alzecurepharma.com

### **About ACD855**

ACD855 is a small molecule drug candidate that improves neurotrophic signalling. Neurotrophins are growth factors involved in mechanisms underlying cognitive function as well as in the function, development and survival of neurons. The neurotrophins are a family of proteins which include e.g nerve growth factor (NGF) and brain derived nerve growth factor (BDNF). ACD855 has demonstrated robust effects on cognitive function in several different preclinical models. Based on those preclinical effects, ACD855 is considered a promising option for the treatment of disease states featuring cognitive decline, such as Alzheimer's disease, sleep disorders, depression and traumatic brain injury.

### **About AlzeCure Pharma**

AlzeCure Pharma AB is a Swedish pharmaceutical company listed on Nasdaq First North Premier, which engages in innovative pharmaceutical research with a primary focus on Alzheimer's disease. The company is developing five drug candidates within its two research platforms NeuroRestore and Alzstatin. NeuroRestore consists of symptomatic drug candidates and Alzstatin consists of disease modifying drug candidates. Through a diversified drug portfolio which targets central signal mechanisms in the brain other indications such as cognitive disorders in traumatic brain injury, sleep apnea and Parkinson's disease are also possible. FNCA Sweden AB is the company's Certified Adviser. For more information, please visit [www.alzecurepharma.se](http://www.alzecurepharma.se).